Azithromycin is a macrolide antibiotic commonly used in outpatient clinics. At present, a clinical use is popular. Azithromycin is orally administered for 3 days and stopped for 4 days. Is this usage correct?   I. When can azithromycin be used? Azithromycin against Gram-positive bacteria (Staphylococcus aureus, Group A hemolytic… Continue Reading Azithromycin, eat 3 days and stop for 4 days, is this usage correct?

  Cimetidine, also known as Methylene guanidine, is a H2 receptor blocker commonly used in primary clinical practice. It has preventive and protective effects against corrosive gastritis caused by chemical stimulation, and stress gastric ulcer and upper digestion. The bleeding also has obvious curative effect and is therefore widely used… Continue Reading 23 clinical new uses of cimetidine

  I. Sulfasalazine Mainly used for inflammatory bowel disease, rheumatoid polyarthritis, hemorrhagic proctitis. 1. Usage and dosage The initial dose is 1~2g per day, divided into 3~4 times orally; in the first few weeks, gradually increase the dose to 3~4g a day, orally 3~4 times; after the symptoms improve, it… Continue Reading The first dose of these drugs must be reduced

  On February 19, Intercept announced that olbecholic acid (OCA) has achieved positive results in the mid-phase analysis of the key phase III REGENERATE study of patients with nonalcoholic steatohepatitis (NASH) with grade 2 to 3 liver fibrosis. Efficacy data from the primary endpoint showed: 1) At the 18th month… Continue Reading NASH’s new drug wins its first phase III clinical victory, and Abecholic acid is about to open a $40 billion market

  On February 14, Merck announced the interim results of the Ib/II umbrella study KEYNOTE-365 at the American Society of Clinical Oncology Urology Tumor Symposium (ASCO GU). KEYNOTE-365 is a developmental, multicenter, multi-cohort, non-randomized study evaluating the efficacy of a fixed dose of Keytruda (200 mg once every 3 weeks)… Continue Reading Merck initiates the largest clinical trial of PD-1/PD-L1 prostate cancer

  Drug: SA-4-1BBL Magazine: Cancer Research Highlights: A new immunotherapy that promises to prevent multiple cancers   T cells play an important role in the defense against cancer, and their activation is regulated by ligand-receptor interactions on macrophages in T cells, dendritic cells, tumor cells, and tumor microenvironments. . These… Continue Reading US scientists confirm for the first time: immunotherapy is expected to prevent multiple cancers

  When BMS paid for the acquisition of Celgene in early January, investors who were not optimistic about the deal considered a big risk that Celgene’s blockbuster drug Revlimid faced a patent challenge and sales would shrink sharply. But a recent US Patent and Trademark Office (PTO) decision has given… Continue Reading The lenalidomide patent challenge threatens to be temporarily lifted! Dr. Reddy’s three patent challenges were invalidated

  Insulin is one of the most important drugs in the history of pharmaceuticals. Since the separation of active insulin from animals by the Canadian doctor Frederick Grant Banting, it has been around for nearly a hundred years and has been continuously upgraded to meet the demand for diabetes. To… Continue Reading After OI388GT terminated the trial, Novo Nordisk deployed oral insulin again, and plans to enter the human clinical clinic within three years.

  Gilead Science announced on February 12 that NASH’s research drug, ASK1 inhibitor selonsertib (GS4997), missed the primary endpoint in its first phase III clinical trial (STELLAR-4). STELLAR-4 is a phase III randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of the NASH new drug selonsertib in patients… Continue Reading Gilead NASH new drug selonsertib first phase III clinical failure

  On February 6, the FDA approved the introduction of Cablivi (caplacizumab-yhdp) injection developed by Sanofi’s subsidiary Ablynx for plasma exchange and immunosuppressive therapy for adult acquired thrombotic thrombocytopenic purpura (aTTP). On September 3, 2018, the European Union has approved the application for the listing of Cablivi for this indication.… Continue Reading FDA approves first Nanobody to treat acquired thrombotic thrombocytopenic purpura